Should I buy Sarepta Therapeutics (SRPT) stock or is it too late?
⭐ The most reliable of them, either direction: HC Wainwright & Co. — 60% of its targets hit on this sector (329 calls tested). It aims for $5 (-70 %), call made on October 6, 2026, maturing on October 6, 2027 (8 d ago).
Firm-by-firm track record on Sarepta Therapeutics
| Firm | % right | Gain vs sector | Calls | Aims for |
|---|---|---|---|---|
| Wedbush | 82 % | +60.1 % | 11 | $34 +106% |
| HC Wainwright & Co. | 80 % | +55.1 % | 15 | $5 -70% |
| Janney Montgomery Scott | 60 % | +27.9 % | 5 | $175 +960% |
| JP Morgan | 60 % | +15.6 % | 15 | $20 +21% |
| Morgan Stanley | 58 % | +12.7 % | 19 | $20 +21% |
| Goldman Sachs | 40 % | +11.8 % | 5 | $19 +15% |
| Citigroup | 50 % | +9.6 % | 12 | $13 -21% |
| Oppenheimer | 36 % | +1.6 % | 11 | $37 +124% |
✅ Reasons to believe
- Median price target $20, i.e. +21% from the current price ($17).
- The most reliable firm on SRPT, Wedbush (82% hit rate, 11 scored calls), targets $34 (call made on January 23, 2026, maturing on January 23, 2027) (+106%) in its most recent call, and $32 (call made on December 9, 2025, maturing on December 9, 2026) (+94%) in the one coming due soonest.
⚠️ Reasons to hesitate
- The consensus is not unanimous: of 6 ratings, 3 are neutral and 2 are sells.
- A 12-month target is not a guaranteed path: the price can fall in the meantime.
- No dividend: your return depends only on price appreciation.
The analyst consensus on SRPT
Median target $20 (+21%) · 6 ratings · Hold consensus
⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.
Frequently asked questions
Should you invest in Sarepta Therapeutics now?
We won't decide for you. The facts: 17% of analysts rate it a buy, median target $20 (+21%), and Wedbush (most reliable on SRPT, 82%) targets $34. Weigh that against valuation. This is not personalized advice.
Is it too late to invest in Sarepta Therapeutics?
Not according to analysts: the median target ($20) is still +21% above the current price ($17) (most reliable on SRPT: Wedbush, 82%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.
Is Sarepta Therapeutics still worth investing in?
It depends on the gap between the price ($17) and its estimated value: analysts target $20 on median (+21%), with 17% buys (most reliable on SRPT: Wedbush, 82%). Cross-check with their real reliability on SRPT and the cautions above. Information, not advice.
What's the main risk in buying SRPT?
The consensus is not unanimous: of 6 ratings, 3 are neutral and 2 are sells.
→ Go deeper: the full Sarepta Therapeutics profile (consensus, analyst reliability, price target, performance).